{"nctId":"NCT00278408","briefTitle":"Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma","startDateStruct":{"date":"2006-01-02"},"conditions":["Lymphoma"],"count":700,"armGroups":[{"label":"Interventional: 6 R-CHOP-21","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: rituximab","Drug: cyclophosphamide","Drug: doxorubicin hydrochloride","Drug: prednisone","Drug: vincristine sulfate"]},{"label":"Interventional: 6 R-CHOP-21 + radiotherapy","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: rituximab","Drug: cyclophosphamide","Drug: doxorubicin hydrochloride","Drug: prednisone","Drug: vincristine sulfate","Radiation: radiation therapy"]},{"label":"Interventional: 6 R-CHOP-14","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: filgrastim","Biological: rituximab","Drug: cyclophosphamide","Drug: doxorubicin hydrochloride","Drug: prednisone","Drug: vincristine sulfate"]},{"label":"Interventional: 6 R-CHOP-14 and radiotherapy","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: filgrastim","Biological: rituximab","Drug: cyclophosphamide","Drug: doxorubicin hydrochloride","Drug: prednisone","Drug: vincristine sulfate","Radiation: radiation therapy"]}],"interventions":[{"name":"filgrastim","otherNames":[]},{"name":"rituximab","otherNames":[]},{"name":"cyclophosphamide","otherNames":[]},{"name":"doxorubicin hydrochloride","otherNames":[]},{"name":"prednisone","otherNames":[]},{"name":"vincristine sulfate","otherNames":[]},{"name":"radiation therapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically confirmed aggressive B-cell non-Hodgkin's lymphoma, including the following subtypes:\n\n  * Grade 3 follicular lymphoma\n  * Diffuse B-cell lymphoma, including diffuse large cell lymphoma with the following variants:\n\n    * Centroblastic\n    * Immunoblastic\n    * Plasmablastic\n    * Anaplastic large cell\n    * T-cell-rich B-cell lymphoma\n  * Primary effusion lymphoma\n  * Intravascular B-cell lymphoma\n  * Primary mediastinal B-cell lymphoma\n  * Burkitt's or Burkitt-like lymphoma\n  * Mantle cell lymphoma (blastoid)\n  * Aggressive marginal zone lymphoma (monocytoid)\n* Previously untreated disease\n* CD20-positive disease\n* International prognostic index (IPI) score 0 or 1 (age-adjusted)\n\n  * Only patients with bulky disease, as defined by largest single or conglomerate tumor ≥ 7.5 cm in diameter, are allowed to have an IPI score of 0\n* No mucosa-associated lymphoid tissue (MALT) lymphoma\n* No CNS involvement of lymphoma (intracerebral, meningeal, or intraspinal)\n\nPATIENT CHARACTERISTICS:\n\n* ECOG performance status 0-2\n* Platelet count ≥ 100,000/mm³\n* WBC ≥ 2,500/mm³\n* No known hypersensitivity to the study medications\n* No known HIV-positivity\n* No active hepatitis infection\n* Not pregnant or lactating\n* Negative pregnancy test\n* No other malignancy within the past 5 years except carcinoma in situ or basal cell skin cancer\n* No impaired left ventricular function\n* No severe cardiac arrhythmias\n* No other impaired organ function\n* No other serious disorder\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior chemotherapy or radiotherapy\n* No prior immunosuppressive treatment with cytostatics\n* No concurrent participation in other treatment studies","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"3 Years Event-free Survival","description":"Event-free survival was the primary endpoint, which was defined as the time from randomization until one of the following events had occurred: progression during therapy, partial response, no change, unknown status at the end of study therapy, relapse after complete response or unconfirmed complete response, death from any cause; or additional treatment, whichever came first.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"56","spread":null},{"groupId":"OG002","value":"126","spread":null},{"groupId":"OG003","value":"123","spread":null},{"groupId":"OG004","value":"89","spread":null},{"groupId":"OG005","value":"92","spread":null}]}]}]},{"type":"SECONDARY","title":"3 Years Progression-free Survival","description":"Progression of disease is defined as: recurrence of disease symptoms, development of new lymphatic or extralymphatic lesions or marked increase in lymphoma manifestation size by more than 25% in comparison with baseline.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"133","spread":null},{"groupId":"OG003","value":"136","spread":null},{"groupId":"OG004","value":"96","spread":null},{"groupId":"OG005","value":"104","spread":null}]}]}]},{"type":"SECONDARY","title":"3 Years Overall Survival","description":"Overall survival was defined as the time from randomization to death of any cause.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"74","spread":null},{"groupId":"OG002","value":"144","spread":null},{"groupId":"OG003","value":"141","spread":null},{"groupId":"OG004","value":"107","spread":null},{"groupId":"OG005","value":"108","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Complete Remissions and Progressive Disease","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"141","spread":null},{"groupId":"OG003","value":"133","spread":null},{"groupId":"OG004","value":"109","spread":null},{"groupId":"OG005","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With a Relapse After a CR/CRu","description":"Relapse is defined as, recurrence of disease symptoms, development of new lymphatic or extralymphatic lesions or a marked increase in lymphoma manifestation size by more thyn 25% after at least 2 months CR or CRu from the time point of the final restaging examination","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"9","spread":null},{"groupId":"OG004","value":"18","spread":null},{"groupId":"OG005","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety (Adverse Events, Serious Adverse Events, Rate of Secondary Neoplasia, Selected Laboratory Parameters, Including Leucocytes, Thrombocytes, and Haemoglobin)","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"8","spread":null},{"groupId":"OG005","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"45","spread":null},{"groupId":"OG003","value":"36","spread":null},{"groupId":"OG004","value":"21","spread":null},{"groupId":"OG005","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"2","spread":null},{"groupId":"OG005","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"10","spread":null},{"groupId":"OG004","value":"2","spread":null},{"groupId":"OG005","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"2","spread":null},{"groupId":"OG005","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"2","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"3","spread":null},{"groupId":"OG005","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"3","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"15","spread":null},{"groupId":"OG004","value":"8","spread":null},{"groupId":"OG005","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Adherence to Protocol - Absolute Dose Vincristine and Prednisone in mg (Median)","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"12","spread":null},{"groupId":"OG004","value":"12","spread":null},{"groupId":"OG005","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3000","spread":null},{"groupId":"OG001","value":"3000","spread":null},{"groupId":"OG002","value":"3000","spread":null},{"groupId":"OG003","value":"3000","spread":null},{"groupId":"OG004","value":"3000","spread":null},{"groupId":"OG005","value":"3000","spread":null}]}]}]},{"type":"SECONDARY","title":"Health-economic Aspects - Number of Patients Who Received Antibiotic Intervention and/or Red Blood Cell and Platelet Transfusion","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"42","spread":null},{"groupId":"OG003","value":"39","spread":null},{"groupId":"OG004","value":"22","spread":null},{"groupId":"OG005","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"14","spread":null},{"groupId":"OG004","value":"4","spread":null},{"groupId":"OG005","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Adherence to Protocol - Total Duration of Chemotherapy in Days (Median)","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"70","spread":null},{"groupId":"OG002","value":"105","spread":null},{"groupId":"OG003","value":"71","spread":null},{"groupId":"OG004","value":"105","spread":null},{"groupId":"OG005","value":"70","spread":null}]}]}]},{"type":"SECONDARY","title":"Adherence to Protocol - Absolute Dose Cyclophosphamide, Doxorubicin and Rituximab in mg/m² (Median)","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4474","spread":null},{"groupId":"OG001","value":"4482","spread":null},{"groupId":"OG002","value":"4464","spread":null},{"groupId":"OG003","value":"4474","spread":null},{"groupId":"OG004","value":"4476","spread":null},{"groupId":"OG005","value":"4455","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"300","spread":null},{"groupId":"OG001","value":"300","spread":null},{"groupId":"OG002","value":"299","spread":null},{"groupId":"OG003","value":"298","spread":null},{"groupId":"OG004","value":"298","spread":null},{"groupId":"OG005","value":"298","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2244","spread":null},{"groupId":"OG001","value":"2232","spread":null},{"groupId":"OG002","value":"2238","spread":null},{"groupId":"OG003","value":"2245","spread":null},{"groupId":"OG004","value":"2242","spread":null},{"groupId":"OG005","value":"2228","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":81},"commonTop":["Leukocytopenia CTC 3, 4","Infection CTC 3-5","Anemia CTC 3, 4","Sensory CTC 3-5","Nausea CTC 3-5"]}}}